Marie Goret
Illkirch-graffenstaden, 67404, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
DNM2 lipid binding drives centronuclear myopathy and represents a potential therapeutic target.
Journal: JCI insight
Published: January 08, 2026
Muscle-Specific DNM2 Overexpression Improves Charcot-Marie-Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle.
Journal: International journal of molecular sciences
Published: December 04, 2025
BIN1 reduction ameliorates DNM2-related Charcot-Marie-Tooth neuropathy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 05, 2025
Combining dynamin 2 myopathy and neuropathy mutations rescues both phenotypes.
Journal: Nature communications
Published: June 07, 2024
The PI3KC2β kinase as a therapeutic target for myotubular myopathy
Journal: Medecine sciences : M/S
Published: February 27, 2024
PI3KC2β: A promising therapeutic target in myotubular myopathy
Journal: Medecine sciences : M/S
Published: November 17, 2023
Potential compensatory mechanisms preserving cardiac function in myotubular myopathy.
Journal: Cellular and molecular life sciences : CMLS
Published: October 09, 2023
Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 04, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026